Computer systems used for clinical trials need to have documented evidence that they are validated systems. This is a formal process that assures users (and regulatory inspectors) that the system is fit for purpose. At MRC CTU, we have successfully met this requirement for the past ten years using the traditional waterfall method of software development, which produces agreed documentation at each stage of the life cycle, in sequential order. However, we often find that requirements for a trial can change during development, which adversely affects timelines and increases the documentation burden. Agile development methods are designed to produce smaller quicker deliverables, which is attractive, but are typically less formal in the documentation produced, which present a challenge when working in a regulated environment. We explore the advantages and disadvantages of several flavours of these methodologies, assembling best practice to optimise efficiency and compliance, and describe the implementation of this methodology in some of our newer trials.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© Rauchenberger et al; licensee BioMed Central Ltd. 2013. This work is published under http://creativecommons.org/licenses/by/2.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
1 MRC Clinical Trials Unit, London, UK (GRID:grid.415052.7) (ISNI:000000040606323X)